您现在的位置: 首页> 研究主题> 噻吗心安

噻吗心安

噻吗心安的相关文献在1989年到2018年内共计99篇,主要集中在眼科学、药学、内科学 等领域,其中期刊论文99篇、专利文献627篇;相关期刊62种,包括眼科新进展、中华实验眼科杂志、中国实用眼科杂志等; 噻吗心安的相关文献由206位作者贡献,包括刘昌东、徐瑞、贾淑琴等。

噻吗心安—发文量

期刊论文>

论文:99 占比:13.64%

专利文献>

论文:627 占比:86.36%

总计:726篇

噻吗心安—发文趋势图

噻吗心安

-研究学者

  • 刘昌东
  • 徐瑞
  • 贾淑琴
  • 陈立军
  • 李健
  • 李树栋
  • 李艳
  • 杨春燕
  • 熊朝晖
  • 王江华
  • 期刊论文
  • 专利文献

搜索

排序:

学科

年份

    • 邓斌
    • 摘要: 目的:研究布林佐胺治疗青光眼的降眼压效果及安全性.方法:选取我院2015年12月—2017年12月收治的88例青光眼患者,随机分为对照组和观察组,每组44例,对照组采用噻吗心安进行治疗,观察组采用布林佐胺进行治疗,分析两组患者治疗前后眼压、血压、心率及不良反应情况.结果:两组患者在治疗前,眼压、降低压无显著性变化(P>0.05),在治疗后,观察组眼压、降低压变化显著高于对照组(P<0.05);两组患者在治疗前,舒张压、收缩压、心率变化无显著性变化(P>0.05),在治疗后,舒张压、收缩压无显著性变化(P>0.05),但是观察组心率显著低于对照组(P<0.05);观察组总不良反应率显著低于对照组总不良反应率(P<0.05).结论:采用布林佐胺治疗,不仅治疗效果好,而且安全性高,同时值得在临床应用中推广.
    • 刘丽娜
    • 摘要: 目的 评价布林佐胺治疗青光眼的临床疗效和安全性.方法 2016年4月~2017年6月至我院收治的青光眼患者57例,随机分为27例对照组及30例观察组,分别给予噻吗心安治疗及布林佐胺治疗.结果 观察组治疗总有效(93.33%)与用药不良情况发生率(3.33%)均明显优于对照组,(P<0.05).结论 对青光眼患者运用布林佐胺进行治疗,具有较为显著的的临床疗效,且安全性较高.
    • 黄蓉; 曹亚云; 杨永健
    • 摘要: 目的:分析比较0.2%阿法根滴眼液与噻吗心安滴眼液患者的临床应用效果.方法:随机分组:观察组33例患者(0.2%阿法根,滴眼液Bid)和对照组32例患者(噻吗心安滴眼液)随访半年.结果:0.2%阿法根和0.5%噻吗心安在降压作用及降压持续作用时间上相似,但0.2%阿法根据有增加眼血流的作用.结论:0.2%在降眼压的同时,具有改善眼血流的作用.
    • 吴起功
    • 摘要: 目的:探讨用曲伏前列素滴眼液联合噻吗心安眼药水治疗原发性开角型青光眼的临床效果。方法:选取在2014年7月至2016年1月期间我院收治的78例原发性开角型青光眼患者,对这78例患者均采用曲伏前列素滴眼液联合噻吗心安眼药水治疗,记录患者在治疗一个月后、三个月后的治疗情况,观察对比患者治疗前后昼夜眼压的变化情况,视野的改变情况以及不良反应情况。结果:在经过一个月、三个月的治疗后,患者的眼压有所下降,视野也有所改善,与治疗前相比有较大差异,P<0.05;患者出现的不良反应有异物感、角膜充血、眼部疼痛、瘙痒等,在治疗一个月后,有15例患者出现轻微的不良反应,且均能耐受,治疗三个月后,有6例患者出现不良反应,并未发生严重后果,且所有患者中均为出现结膜炎、角膜炎、眼睑炎、全身不适等不良反应。结论:在临床上,采用曲伏前列素滴眼液联合噻吗心安眼药水治疗原发性开角型青光眼的疗效较佳,且不良反应发生较少,一般不会出现严重不良反应,整体治疗效果令人满意,能够有效的减轻患者痛苦,缓解症状,值得在临床上广泛应用。
    • 赵艳霞
    • 摘要: 目的::研究拉坦前列素联合噻吗心安治疗方案对开角型青光眼视觉功能、眼压、眼血流的影响。方法:将2012-01/2014-05期间在我院眼科收治的开角型青光眼患者50例59眼纳入研究对象,采用数字表法随机分为观察组和对照组,观察组患者给予拉坦前列素联合噻吗心安治疗,对照组患者给予噻吗心安治疗,比较两组患者的视觉功能、眼压、眼血流情况。结果:治疗后1,2,3,4wk,观察组患眼白天平均眼压、夜间平均眼压均明显低于对照组,视力水平(0.27±0.03,0.36±0.06,0.44±0.06,0.63±0.13)明显高于对照组;观察组患眼的收缩期峰值血流速度(14.41±1.73cm/s)、舒张末期血流速度(4.18±0.67cm/s)均明显高于对照组,血管阻力指数(0.58±0.07)明显低于对照组。结论:拉坦前列素联合噻吗心安能够更为有效降低眼压,增加视网膜中央动脉的血流量,降低血管阻力,改善视力水平。%Abstract•AlM: To study the effect of latanoprost combined with timolol treatment on visual function, intraocular pressure and ocular blood flow of open angle glaucoma.•METHODS:A total of 50 cases ( 59 eyes ) with open angle glaucoma were enrolled from January 2012 to May 2014 in our hospital department of ophthalmology, and divided into observation group and control group by adopting the random number table method. Patients in observation group were treated with latanoprost combined with timolol, patients in control group were treated only with timolol. Visual function, intraocular pressure and ocular blood flow were compared.•RESULTS:1, 2, 3 and 4wk after treatment, observation group during the day intraocular pressure, night intraocular pressure were significantly lower than that in control group, vision levels (0. 27±0. 03, 0. 36±0. 06, 0. 44± 0. 06, 0. 63 ± 0. 13 ) were significantly higher than that in control group; observation group peak systolic velocity (14. 41± 1. 73) cm/s, end diastolic velocity (4. 18 ± 0. 67) cm/s were significantly higher than that in control group;vascular resistance index ( 0. 58 ± 0. 07 ) was significantly lower than that in control group.• CONCLUSlON: Latanoprost combined with timolol treatment can reduce intraocular pressure, increase blood flow of central retinal artery, reduce vascular resistance, improve visual acuity.
    • 高文清
    • 摘要: 目的:研究拉坦前列腺素对原发性开角型青光眼(POAG)患者的治疗效果.方法:POAG患者135例,随机分为观察组(n=70)和对照组(n=65),观察组给予拉坦前列腺素治疗,对照组给予噻吗心安治疗;记录2组患者治疗前后的眼压及波动值、视野缺损及视网膜纤维层(RNFL)厚度及不良反应.结果:两组患者治疗后昼夜平均眼压、眼压波动值及视野缺损范围均较治疗前明显降低,差异有统计学意义(P<0.05);治疗后观察组昼夜平均眼压、眼压波动值较对照组降低更明显,下方视野、颞侧视野及鼻侧视野缺损范围较对照组明显缩小,上方视盘、下方视盘、颞侧视盘及鼻侧视盘较对照组明显增厚,差异均有统计学意义(P<0.05);治疗后观察组9例(12.86%)、对照组11例(16.92%)出现不良反应,差异无统计学意义(P>0.05).结论:拉坦前列腺素治疗原发性开角型青光眼效果优于噻吗心安.
    • 吴杨杨; 宋胜仿; 李华; 吕莎
    • 摘要: AIM:To evaluate the efficacy and safety of latanoprost versus timolol for primary open angle glaucoma ( POAG) and ocular hypertension ( OHT) . METHODS: This was an evidence -based medicine science study.Pertinent studies of randomized controlled trial ( RCT) were identified through searches of PubMed, Medline, CNKI and China Biology Medicine disc. The intensive searching by hand and internet was also designed.According to inclusion and exclusion criteria, the study object was limited.Quality of literatures were evaluated by experienced researchers according to the Jadad Score.RevMan 5.0 offered by Cochrane was used for Meta-analysis aimed at the ratio of low intraocular tension and adverse drug reaction. RESULTS: A total of 9 RCT sadded up to 555 patients were involved.The results of meta-analysis showed that, a) the difference at 2, 6, 12wk both had statistical significance, latanoprost showed greater intraocular pressure ( IOP) lowering efficacy compared with timolol. The weighted mean difference (WMD) at 2, 6, 12wk was respectively [-0.76, 95% CI (-1.32 to -0.20)], [-1.15, 95%CI (-1.68 to 0.63)] and [-1.01, 95%CI (-1.42 to-0.61)]. b) The difference in conjunctival congestion ( OR=2.25, 95% CI 0.99 to 5.08) and foreign body sensation ( OR=2.48, 95% CI 1.02 to 6.03 ) between latanoprost and timolol group was not statistically significant. CONCLUSION: Latanoprost showed greater IOP lowering efficacy at 12wk compared with timolol for OAG and OH patients. The conjunctival hyperemia, foreign body sensation, iris pigmentation deepened, vision damage of latanoprost group at 12wk compared with timolol, the difference was not significant. This conclusion is not powerful enough in proof due to the medium methodology quality of the included studies, so a large number of high-quality RCTs with large sample are needed for objectively, precisely and entirely evaluating the efficacy.%目的:系统评价拉坦前列素( Latanoprost )滴眼液与噻吗心安(Timolol)滴眼液降眼压的有效性和安全性。  方法:计算机检索PubMed,Medline,CNKI及中国生物医学文献数据库收录的,并辅以手工检索、因特网搜索的有关拉坦前列素与噻吗心安治疗原发性开角型青光眼和高眼压症的随机对照试验( RCT )。按照纳入和排除标准限定研究对象,通过Jadad 评分量表进行文献质量评估后,针对眼压下降比例、药物不良反应2项内容,使用Cochrane协作网提供的RevMan 5.0软件进行Meta分析。  结果:共纳入9项RCT,合计555例患者。 Meta分析结果显示:(1)拉坦前列素滴眼液与噻吗心安滴眼液降眼压效果,在2,6,12wk时差异均有统计学意义( P<0.01),加权平均差(WMD)分别为:在2wk[WMD=-0.76,95%CI(-1.32,-0.20)],在6wk[WMD=-1.15,95%CI(-1.68,0.63)]和12wk[WMD=-1.01,95%CI(-1.42,-0.61)]。(2)随访结束时,结膜充血、异物感为拉坦前列素的两种较为常见的不良反应,但其发生率拉坦前列素组与噻吗心安组比较,结膜充血的发生率[OR=2.25,95%CI(0.99,5.08)],异物感的发生率[OR=2.48,95%CI(1.02,6.03)],显示二者差异均无统计学意义。  结论:治疗原发性开角型青光眼和高眼压症,拉坦前列素降眼压效果在用药12 wk内较噻吗心安好;两者在12 wk内引起结膜充血、异物感、虹膜色素加深、视野损害等的不良反应方面,差异不明显。由于纳入研究的样本量偏小,且方法学质量中等,致使本系统评价结果论证强度不高,因此还需要开展更多的高质量的临床随机对照研究,以便更客观、准确、全面地评价其疗效和安全性。
    • 贾淑琴; 徐瑞
    • 摘要: 青光眼作为全球第2位不可逆的致盲眼病,具有终身性和进展性等特点。因此一旦明确诊断,就要采取积极的治疗措施来保护视功能免受进一步的损害。青光眼的早期主要治疗手段是药物治疗。噻吗心安滴眼液作为β-肾上腺素能受体阻滞剂的代表药物已经被包括美国在内的多国指南推荐为首选药物。但单一使用的临床效果并不十分满意。我科在使用噻吗心安滴眼液的同时加用适利达滴眼液取得了较好的疗效,现报告如下。
    • 胡杨; 赵鸣; 丁洁
    • 摘要: 目的 研究拉坦前列素及噻吗心安治疗开角型青光眼的疗效及安全性.方法 将120例开角型青光眼患者纳入研究对象,随机分为给予拉坦前列素联合噻吗心安治疗的观察组和单独给予噻吗心安治疗的对照组,检测视野缺损情况、视网膜神经纤维层厚度并观察不良反应例数.结果 (1)观察组患者的上方视野(4.9±0.8) dB、下方视野(5.1±0.9)dB、颞侧视野(7.2±1.3)dB、鼻侧视野缺损(6.9± 1.1) dB均明显低于对照组(P<0.05);(2)观察组患者的上方视野(92.3±13.2)μm、下方视野(90.8± 12.1) μm、颞侧视野(74.2±10.3)μm、鼻侧视野RNFL厚度(70.8±12.3)μm均明显高于对照组(P<0.05);(3)两组患者发生不良反应例数比较差异无统计学意义(P> 0.05).结论 拉坦前列素及噻吗心安治疗开角型青光眼有助于改善视野缺损和视网膜神经纤维层厚度,且保证相当的安全性,具有积极的临床价值.%Objective To study the efficacy and safetv of latanoprost and timolol maleate in treating open angle glaucoma.Methods Open angle glaucoma patients were enrolled and randomly divided into observation group (given latanoprost and timolol maleate) and control group (given timolol maleate).Then RNFL thickness,visual field defect degree were detected and adverse reaction was observed.Results ① Field defect in above view field,lower visual field,visual field,nasal visual field of observation group were lower than those of control group; ② RNFL thickness in above view field,lower visual field,visual field,nasal visual field of observation group were higher than those of control group; ③There were no statistical significant difference found in incidence of adverse reaction cases between two groups.Conclusion Latanoprost and timolol maleate have positive clinical value for it can improve RNFL thickness,visual field defect and achieve equal safety.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号